Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
CONCLUSIONS In this small group of patients, the preliminary results indicate that a regression of fibrosis is achievable within 24 weeks of therapy with SOF after OLT. SOF seems to be effective and safe in the treatment of OLT patients infected with HCV and will likely improve patient and transplant survival.
PMID: 26391423 [PubMed - as supplied by publisher] (Source: Annals of Transplantation)
Source: Annals of Transplantation - September 25, 2015 Category: Transplant Surgery Authors: Seifert LL, Vorona E, Bester C, Stahl M, Hüsing A, Beckebaum S, Kabar I, Heinzow H, Schmidt HH Tags: Ann Transplant Source Type: research
Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: AN early access programme
HPC3005 is a multicentre, open-label, telaprevir trial in HCV/HIV coinfected patients with severe fibrosis or compensated cirrhosis. (Source: Journal of Infection)
Source: Journal of Infection - September 25, 2015 Category: Infectious Diseases Authors: Andrea Gori, Manuela Doroana, Oksana Chernova, Jürgen K. Rockstroh, Denes Banhegyi, Colm Bergin, Gabriella Verucchi, Chris Liu, Ralph DeMasi, Blanca Hadacek, Mark Nelson Source Type: research
Viruses, Vol. 7, Pages 5155-5168: Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance
Hepatitis C virus (HCV) infection is one of the leading causes of end-stage liver disease and the main indication for liver transplantation (LT) in most countries. All patients who undergo LT with detectable serum HCV RNA experience graft reinfection progressing to cirrhosis within five years in 20% to 30% of them. Obtaining a sustained virological response (SVR) greatly improves overall and graft survival. Until 2011, standard antiviral therapy using PEGylated interferon (PEG-IFN) and ribavirin (RBV) was the only effective therapy, with an SVR rate around 30% in this setting. For patients infected with genotype 1, first ...
Source: Viruses - September 23, 2015 Category: Virology Authors: Bruno RocheAudrey CoillyAnne-Marie Roque-AfonsoDidier Samuel Tags: Review Source Type: research
Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
by Audrey Coilly, Jérôme Dumortier, Danielle Botta-Fridlund, Marianne Latournerie, Vincent Leroy, Georges-Philippe Pageaux, Hélène Agostini, Emiliano Giostra, Christophe Moreno, Bruno Roche, Teresa Maria Antonini, Olivier Guillaud, Pascal Lebray, Sylvie Radenne, Anne-Catherine Saouli, Yvon Calmus, Laurent Alric, Maryline Debette-Gratien, Victor De Ledinghen, François Durand, Christophe Duvoux, Didier Samuel, Jean-Charles Duclos-Vallée
Background and aims First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype...
Source: PLoS One - September 22, 2015 Category: Biomedical Science Authors: Audrey Coilly et al. Source Type: research
Determination of the HCV Protease Inhibitor Telaprevir in Plasma and Dried Blood Spot by Liquid Chromatography–Tandem Mass Spectrometry
The objective of this work was to develop liquid chromatography–tandem mass spectrometer (LC–MS/MS) assays for telaprevir both in plasma and in dried blood spot (DBS), capable of stabilizing the equilibrium and chromatographically separating the 2 epimers.
Methods: Human plasma was acidified with formic acid and frozen within 1 hour after collection to stabilize the equilibrium between the 2 telaprevir diastereomers ex vivo in plasma. After protein precipitation, the sample was analyzed with LC–MS/MS. For the DBS assay, sampling paper was impregnated with citric acid solution to achieve stabilization of the epimers o...
Source: Therapeutic Drug Monitoring - September 18, 2015 Category: Drugs & Pharmacology Tags: Original Article Source Type: research
Does boceprevir really increase the risk of skin eruptions during antihepatitis C treatment?
This article is protected by copyright. All rights reserved.
PMID: 26369272 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - September 15, 2015 Category: Dermatology Authors: Carrascosa R, Llamas-Velasco M, Montes-Torres A, Sánchez-Pérez J Tags: Br J Dermatol Source Type: research
Decrease of renal function in HCV and HIV/HCV-infected patients with telaprevir-based therapy
No abstract available (Source: AIDS)
Source: AIDS - September 11, 2015 Category: Infectious Diseases Tags: Correspondence Source Type: research
Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy
Conclusion IFN-based therapy for chronic HCV affects NK cell phenotype in peripheral blood more than in the liver. (Source: Antiviral Therapy)
Source: Antiviral Therapy - September 10, 2015 Category: Virology Source Type: research
Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
CONCLUSION: IFN-based therapy for chronic HCV affects NK cell phenotype in peripheral blood more than in the liver.
PMID: 26363298 [PubMed - as supplied by publisher] (Source: Antiviral Research)
Source: Antiviral Research - September 9, 2015 Category: Virology Authors: Spaan M, van Oord GW, Janssen HL, de Knegt RJ, Boonstra A Tags: Antiviral Res Source Type: research
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
ConclusionsThe findings of these analyses support the use of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in these subpopulations with cirrhosis. Genotype 1a‐infected patients with indicators of portal hypertension may benefit from a 24‐week treatment duration. (Source: Liver International)
Source: Liver International - September 6, 2015 Category: Gastroenterology Authors: Xavier Forns, Fred Poordad, Marcos Pedrosa, Marina Berenguer, Heiner Wedemeyer, Peter Ferenci, Mitchell L. Shiffman, Michael W. Fried, Sandra Lovell, Roger Trinh, Juan Carlos Lopez‐Talavera, Gregory Everson Tags: Rapid Communication Source Type: research
Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection.
CONCLUSION: Telaprevir and boceprevir retain their place among potential treatment strategies in HIV-HCV coinfected patients including those with advanced compensated liver disease and who failed previous PegIFN/RBV therapy.
PMID: 26328030 [PubMed] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - September 5, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
Treatment of HCV in Patients who Failed First-Generation PI Therapy: a Review of Current Literature
Abstract
The addition of the first direct-acting antiviral agents, the NS3 protease inhibitors boceprevir or telaprevir, to peg interferon and ribavirin was a major advance in the treatment of genotype 1 hepatitis C individuals with sustained virological response (SVR) rates of 63–75 %. Those who did not achieve SVR had high rates of resistance-associated variants against NS3 protease domain. Retreatment options for those who have failed first-generation protease inhibitors generally are guided by retreatment with direct-acting antiviral agents from other classes. Phase 2 and phase 3 data have demons...
Source: Current Gastroenterology Reports - September 5, 2015 Category: Gastroenterology Source Type: research
Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
Abstract: We investigated the safety, efficacy, and impact of ribavirin and peginterferon dose reduction on complete early virologic response and sustained virologic response (SVR) to triple therapy with telaprevir in treatment-experienced patients with advanced liver fibrosis.
Treatment was initiated for 211 patients who failed treatment with peginterferon and ribavirin, with bridging fibrosis (F3, n = 68) or cirrhosis (F4, n = 143), including 103 (49%) null-responders (NR), 30 (14%) partial responders (PR), and 78 (37%) relapsers (REL). Impaired liver function (ILF) platelets (Source: Medicine)
Source: Medicine - September 1, 2015 Category: Internal Medicine Tags: Research Article: Observational Study (STROBE Compliant) Source Type: research
